# Premenstrual Dysphoric Disorder

Confirm PMDD with prospective daily ratings before attributing cyclic symptoms to a primary mood disorder. Distinguish PMDD from premenstrual exacerbation, assess suicidality urgently, and select SSRIs, ovulation suppression, or CBT according to symptom pattern, contraceptive needs, comorbidity, and treatment response.

**Clinical question:** How should clinicians confirm PMDD, exclude premenstrual exacerbation and alternative causes, and choose initial versus refractory treatment?

Updated: 2026-09-15T17:23:47.835472+00:00

## What matters in practice
- Do not diagnose PMDD from retrospective history alone; use daily prospective symptom ratings for at least 2 symptomatic cycles, with the DRSP as a validated practical instrument. [12][14][17]
- PMDD requires at least 5 symptoms, including at least 1 core affective symptom, occurring premenstrually, improving soon after menses begins, and becoming minimal or absent after menses; clinically significant impairment is required. [16][18]
- A persistent disorder with premenstrual worsening is premenstrual exacerbation (PME), not PMDD alone; assess baseline symptoms and treat the underlying mood, anxiety, or personality disorder concurrently. [14][16]
- Assess suicidal ideation and acute psychiatric distress at presentation; these warrant urgent mental-health evaluation rather than waiting for prospective charting. [17]
- SSRIs are first-line pharmacotherapy; continuous and luteal-phase regimens are both supported, although a recent Cochrane review found continuous dosing may be more effective. [5][19]
- For patients desiring hormonal contraception, drospirenone-containing combined oral contraception is a therapeutic option; hormonal mood effects are heterogeneous, so reassess mood after initiation. [2][3]

## Address acute risk while establishing a provisional diagnosis

Do not delay safety assessment while awaiting two-cycle symptom confirmation.

At the initial visit, directly assess suicidal ideation, intent, plan, prior attempts, psychosis, mania or hypomania, substance use, and inability to maintain safety. Suicidal ideation or significant psychiatric distress requires prompt mental-health evaluation and safety intervention; prospective charting is used to confirm cyclicity, not to defer acute care. [17]

A retrospective history can justify a provisional PMDD diagnosis and initial symptom-directed treatment, but it does not establish the diagnosis. Ask the patient to identify the first day of bleeding, symptom-free days, use of hormonal contraception, and whether clinically important depression, anxiety, irritability, or interpersonal dysfunction persists outside the luteal phase. Prospective daily ratings across at least 2 consecutive symptomatic cycles must confirm the diagnosis. [14][16][18]

Review drugs and exposures that can produce mood symptoms, and assess medical alternatives when indicated by history or examination. DSM-based criteria require that symptoms not be attributable to a substance, medication, other treatment, or medical disorder; hyperthyroidism is a named alternative medical explanation. [14][18]
- Document cycle timing, bleeding pattern, pregnancy possibility, hormonal regimen, and psychiatric treatment before interpreting diary data. [16][17]
- If bipolar-spectrum illness is suspected from a history of mania or hypomania, avoid treating the presentation as isolated PMDD without psychiatric assessment; bipolar disorder is a frequent diagnostic overlap. [4]
- Use the prospective diary interval to establish a safety plan, initiate indicated treatment, and arrange follow-up rather than offering reassurance alone. [17]

*Initial triage priorities for suspected PMDD. [17]*

| Finding | Interpretation | Immediate action |
| --- | --- | --- |
| Suicidal ideation, plan, intent, or inability to maintain safety | Acute psychiatric risk may coexist with a menstrual-cycle disorder. [17] | Perform urgent safety assessment and obtain prompt mental-health evaluation. [17] |
| Mania, hypomania, psychosis, or major noncyclic mood symptoms | Consider bipolar-spectrum or another primary psychiatric disorder rather than isolated PMDD. [4][16] | Obtain psychiatric assessment and chart daily symptoms across the cycle. [14][16] |
| Clear luteal symptoms but no prospective documentation | PMDD may be diagnosed provisionally only. [14][16][18] | Begin daily DRSP ratings for at least 2 symptomatic cycles. [12][17] |

## Confirm the cyclic pattern with daily DRSP ratings

The diagnostic discriminator is a symptom-free or near-symptom-free postmenstrual interval.

Use the Daily Record of Severity of Problems (DRSP) each day for at least 2 consecutive symptomatic cycles. The DRSP includes 24 items: 21 items spanning 11 symptom domains and 3 items addressing functional impairment; each item is rated from 1, not at all, to 6, extreme. This prospective record is more reliable than retrospective symptom recall and establishes timing, severity, and functional consequences. [15][17]

Confirm DSM-pattern timing: symptoms occur in the final week before menses, improve within a few days after menstrual bleeding begins, and become minimal or absent in the week after menses. Symptoms must be present in most menstrual cycles over the preceding year, although prospective two-cycle documentation is the required confirmation step. [16][18]

Require at least 5 of 11 symptoms, including at least 1 core affective symptom: affective lability, irritability or anger, depressed mood or hopelessness, or anxiety or tension. Additional qualifying symptoms include diminished interest, concentration difficulty, low energy, appetite change, sleep disturbance, feeling overwhelmed or out of control, and physical symptoms. The symptoms must cause clinically significant distress or impairment in work, school, social activities, or relationships. [16][18]
- Record functional impairment separately; symptom count without clinically significant impairment does not establish PMDD. [14][16]
- Use C-PASS when available to standardize interpretation of daily ratings across symptom content, severity, cyclicity, and chronicity. [14][15]
- C-PASS operationalizes a qualifying symptom as at least moderate severity, a rating of 4 on its 1-to-6 scale, for at least 2 days in the premenstrual week. [15]

*PMDD diagnostic elements to apply to prospective daily ratings. [14][16][18]*

| Element | Required finding | Clinical implication |
| --- | --- | --- |
| Timing | Symptoms peak in the final premenstrual week, improve within days after bleeding begins, and are minimal or absent the following week. [16][18] | A continuous symptom burden argues against isolated PMDD. [14][16] |
| Symptom burden | At least 5 of 11 symptoms, including at least 1 core affective symptom. [16][18] | Fewer qualifying symptoms may represent another menstrual-related disorder rather than PMDD. [15] |
| Severity | Clinically significant distress or functional impairment. [14][16] | Treat impairment as a diagnostic criterion, not an optional severity descriptor. [14] |
| Prospective confirmation | Daily ratings for at least 2 symptomatic cycles. [12][14][16] | A provisional diagnosis may precede confirmation. [14][16][18] |

## Distinguish PMDD from premenstrual exacerbation

The key branch point is whether symptoms remit outside the luteal phase.

Premenstrual exacerbation is worsening of an existing psychiatric disorder before menses, whereas PMDD requires a distinct cyclical pattern with symptoms minimal or absent after menses. Major depressive disorder, persistent depressive disorder, panic disorder, anxiety disorders, and personality disorders can coexist with PMDD but cannot be relabeled PMDD if the diary shows substantial symptoms throughout the cycle. [14][16]

Use daily ratings to compare premenstrual symptom burden with the postmenstrual week rather than relying on a report that symptoms are “worse before the period.” In research applying C-PASS, clinically significant PME was operationalized as at least a 30% premenstrual increase relative to the postmenstrual week for an emotional symptom; this quantifies worsening but does not substitute for the full PMDD diagnostic pattern. [13]

In patients with borderline personality disorder, daily DRSP data may reveal meaningful premenstrual elevations in depression, anxiety, anger, rejection sensitivity, or interpersonal conflict. This pattern should prompt treatment of the baseline personality disorder and risk assessment in addition to cycle-specific interventions; it should not be assumed to represent PMDD without the required symptom-free interval and full criteria. [13][14][16]
- Screen for current depression, anxiety, panic symptoms, trauma-related symptoms, and bipolar-spectrum history before attributing all mood change to PMDD. [4][14][16]
- If daily ratings demonstrate a persistent baseline disorder plus premenstrual worsening, document PME and optimize treatment of the underlying disorder rather than using intermittent therapy as the sole strategy. [14][16]
- If medication adverse effects, substance exposure, or a medical disorder temporally explains symptoms, do not diagnose PMDD until that alternative explanation is addressed. [14][18]

*Diary-based distinction between PMDD and common mimics. [13][14][16][18]*

| Pattern | Daily-rating finding | Next step |
| --- | --- | --- |
| PMDD | At least 5 qualifying symptoms with luteal-phase onset, postmenstrual remission, and impairment. [16][18] | Initiate PMDD-directed treatment while monitoring diary response. [17][19] |
| Premenstrual exacerbation | Underlying symptoms remain outside the luteal phase but intensify premenstrually; a 30% premenstrual increase is one C-PASS research threshold for emotional symptoms. [13][14] | Treat the baseline psychiatric disorder and address cyclic worsening. [14][16] |
| Medication, substance, or medical cause | Timing is better explained by an exposure, treatment, or condition such as hyperthyroidism. [14][18] | Evaluate and correct the alternative cause before assigning PMDD. [14][18] |

## Choose first-line treatment by symptom pattern and contraceptive goals

SSRIs and selected combined oral contraceptives are principal medication options.

Offer an SSRI as first-line pharmacotherapy when mood symptoms or functional impairment are clinically significant. Fluoxetine, sertraline, and paroxetine are the SSRIs identified as FDA-approved in the United States for severe PMS/PMDD. SSRIs have rapid PMDD symptom effects, reported within 1 to 2 days, permitting either continuous administration or treatment confined to the luteal phase. [10][19]

Select continuous SSRI dosing when symptoms extend beyond the luteal phase, when PME or another depressive or anxiety disorder is present, or when a patient prefers a consistent regimen. Luteal-phase dosing, typically begun 10 to 14 days before anticipated menses, can reduce medication exposure and adverse effects for patients with a clearly limited premenstrual symptom window. A 2024 Cochrane review of 34 randomized trials concluded that SSRIs reduce PMDD symptoms and that continuous dosing may be more effective than intermittent dosing. [5][19]

Before prescribing, discuss nausea, insomnia, fatigue, nervousness, headache, and sexual dysfunction. Reassess daily ratings, adverse effects, adherence, functional impairment, and suicidal thinking after treatment initiation; use the same prospective instrument to determine whether the premenstrual symptom peak and impairment have diminished. [17][19]

For patients who desire contraception and do not have contraindications to combined hormonal contraception, a drospirenone-containing combined oral contraceptive is a reasonable hormonal option. Hormonal effects on mood are not uniform: some individuals improve while others worsen, so establish a baseline diary and reassess after initiation rather than presuming a class-wide psychiatric effect. [2][3]
- Use cognitive-behavioral therapy as a nonpharmacologic treatment option, particularly when the patient prefers psychotherapy, has medication intolerance, or needs coping and behavioral strategies; benefits for premenstrual symptoms have been reported without recorded adverse effects. [1][21]
- Regular exercise, stress reduction, and structured lifestyle interventions can be offered as adjuncts, but they should not replace SSRI treatment or urgent psychiatric intervention in severe, functionally impairing illness. [1][2]
- When initiating a combined oral contraceptive in a patient with substantial mood symptoms, give explicit instructions to report mood deterioration or new suicidal ideation promptly. [3][7]

*Treatment selection for confirmed or provisionally diagnosed PMDD. [1][2][3][5][10][19]*

| Clinical situation | Preferred approach | Key tradeoff or monitoring |
| --- | --- | --- |
| Predominantly luteal symptoms; no important symptoms outside that interval | Consider luteal-phase SSRI treatment, started approximately 10 to 14 days before menses. [19] | May reduce adverse-effect exposure; confirm symptom timing with daily ratings. [17][19] |
| PME, comorbid depression or anxiety, or symptoms beyond the luteal phase | Prefer continuous SSRI treatment. [5][14][16] | Continuous dosing may be more effective than intermittent dosing and treats baseline symptoms. [5] |
| Needs effective contraception and seeks hormonal treatment | Consider a drospirenone-containing combined oral contraceptive. [2][3] | Mood may improve or worsen; reassess prospectively after initiation. [3] |
| Prefers nonpharmacologic treatment or cannot tolerate medication | Offer CBT; add exercise and stress-reduction strategies. [1][2][21] | Monitor functional outcomes and diary scores rather than assuming symptom control. [17] |

## Reserve ovulation suppression for refractory, confirmed PMDD

Escalate only after reconfirming diagnosis, adherence, comorbidity, and treatment target.

Before labeling PMDD refractory, review the prospective diary for a true postmenstrual remission, determine whether the apparent failure is actually PME or an untreated baseline disorder, and verify the treatment schedule and tolerability. This reassessment matters because diagnostic overlap with depression, anxiety, bipolar disorder, and personality disorders is common. [4][14][16]

Gonadotropin-releasing hormone agonists suppress ovulation and usually decrease PMDD symptoms; they are a hormonal suppression option for refractory illness rather than routine initial therapy. Their use should follow confirmation of a cycle-linked disorder and a careful discussion of the consequences of abolishing ovarian hormone fluctuations and the safety implications of longer-term hormonal suppression. [2][8][20]

Refer patients with persistent severe impairment, uncertain bipolar-spectrum illness, suicidal symptoms, complex psychiatric comorbidity, or failure of SSRI and contraceptive-based strategies to clinicians with reproductive psychiatry and gynecology expertise. The referral question should specify whether the diary demonstrates PMDD, PME, or both, because that distinction determines whether continuous psychiatric treatment, hormonal suppression, or combined care is needed. [4][14][16]
- Use the DRSP or another daily instrument longitudinally after every major treatment change to document response and detect persistent noncyclic symptoms. [17]
- Do not use ovulation suppression as a diagnostic shortcut when daily ratings do not show the required timing and remission pattern. [14][16][18]
- Reassess suicidality whenever symptoms intensify, treatment is changed, or hormonal therapy is initiated in a patient with prior mood instability. [3][7][17]

*Escalation checkpoints in persistent PMDD symptoms. [4][14][16][17][20]*

| Checkpoint | Question to answer | Action if abnormal |
| --- | --- | --- |
| Diagnostic confirmation | Do ratings show luteal symptoms with postmenstrual remission for at least 2 symptomatic cycles? [14][16] | Reclassify as PME or another disorder when symptoms remain clinically significant outside the luteal phase. [14][16] |
| Psychiatric comorbidity | Are depression, anxiety, bipolar-spectrum illness, or personality disorder contributing? [4][14] | Treat the baseline disorder and involve psychiatry when indicated. [4][14][16] |
| Failure of initial options | Has an SSRI regimen and, when appropriate, a contraceptive strategy been adequately evaluated with daily ratings? [5][17] | Consider specialist-directed ovulation suppression with a GnRH agonist for refractory confirmed PMDD. [2][8][20] |

## References
1. Help-seeking behaviours and experiences for mental health symptoms related to the menstrual cycle: a UK-wide exploratory survey | npj Women's Health — www.nature.com — https://www.nature.com/articles/s44294-023-00004-w
2. Premenstrual Syndrome and Dysphoric Disorder Management | Psychiatry | Clinical Sciences | Health sciences | Topics | Nature Index — www.nature.com — https://www.nature.com/nature-index/topics/l4/premenstrual-syndrome-and-dysphoric-disorder-management
3. The impact of ovulation-suppressing contraceptives on behavioral and functional difficulties in borderline personality disorder | Neuropsychopharmacology — www.nature.com — https://www.nature.com/articles/s41386-024-02045-4
4. Premenstrual dysphoric disorder in online peer support communities: a Reddit case study | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-025-19220-2
5. Evaluation and management of premenstrual dysphoric disorder ... — journals.lww.com — https://journals.lww.com/10.1097/MOP.0000000000001563
6. Premenstrual disorders including premenstrual... : The Obstetrician & Gynaecologist — journals.lww.com — https://journals.lww.com/01034179-202325010-00008
7. Abstracts of Scientific Papers and Posters... : American Journal of Physical Medicine & Rehabilitation — journals.lww.com — https://journals.lww.com/ajpmr/fulltext/2016/03001/abstracts_of_scientific_papers_and_posters.1.aspx
8. [PDF] Guideline on the treatment of Premenstrual Dysphoric Disorder ... — www.ema.europa.eu — https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-treatment-premenstrual-dysphoric-disorder-pmdd_en.pdf
9. London, 19 February 2009 Doc. Ref. EMEA/CHMP/EWP ... — www.ema.europa.eu — https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-guideline-treatment-premenstrual-dysphoric-disorder-pmdd_en.pdf
10. Menstrual Disorders | AAP Books | American Academy of Pediatrics — publications.aap.org — https://publications.aap.org/aapbooks/book/672/chapter/8113772/Menstrual-Disorders
11. Menstrual Disorders: Dysmenorrhea and Premenstrual ... — publications.aap.org — https://publications.aap.org/book/chapter-pdf/795262/aap_9781581105650-part02-ch63.pdf
12. Navigating Unique Diagnostic and Therapeutic Challenges in Premenstrual Dysphoric Disorder: A Case Report - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11281859
13. Perimenstrual Exacerbation of Symptoms in Borderline Personality Disorder: Evidence from Multilevel Models and the Carolina Premenstrual Assessment Scoring System — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6436806
14. Diagnostic validity of premenstrual dysphoric disorder: revisited — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10711063
15. Making Strides to Simplify Diagnosis of Premenstrual Dysphoric Disorder - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC5291290
16. Premenstrual Disorders - Abstract - Europe PMC — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/30335340
17. Premenstrual Disorders - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK532307
18. Table 1, Diagnostic Criteria for Premenstrual Dysphoric Disorder (PMDD) - Endotext - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK279045/table/premenstrual-syndrom.table1diag
19. Premenstrual dysphoric disorder: A review for the treating ... — www.ccjm.org — https://www.ccjm.org/content/ccjom/71/4/303.full.pdf
20. Women and headache: A treatment approach based on life ... — www.ccjm.org — https://www.ccjm.org/content/ccjom/69/6/488.full.pdf
21. Emotion Dysregulation of Women with Premenstrual Syndrome | Scientific Reports — www.nature.com — https://www.nature.com/articles/srep38501
22. Differential grey matter structure in women with premenstrual dysphoric disorder: evidence from brain morphometry and data-driven classification | Translational Psychiatry — www.nature.com — https://www.nature.com/articles/s41398-022-02017-6
23. Brain reactivity during aggressive response in women with premenstrual dysphoric disorder treated with a selective progesterone receptor modulator | Neuropsychopharmacology — www.nature.com — https://www.nature.com/articles/s41386-021-01010-9
24. Online positive-oriented counseling, taking vitamin D3 tablet, online lifestyle modification training on premenstrual syndrome: a 3-armed randomized clinical trial | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-023-43940-y

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.